| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 968 | CTRPv2 | pan-cancer | AAC | -0.092 | 0.2 |
| mRNA | Rapamycin | gCSI | pan-cancer | AAC | -0.091 | 0.1 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.09 | 0.02 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | -0.09 | 0.01 |
| mRNA | simvastatin | CTRPv2 | pan-cancer | AAC | -0.089 | 0.02 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.087 | 0.1 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | -0.087 | 0.06 |
| mRNA | GW843682X | GDSC1000 | pan-cancer | AAC | -0.087 | 0.09 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | -0.086 | 0.3 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.086 | 0.06 |